Login to Your Account



Perjeta Nod Boosts HER2 Portfolio in Breast Cancer

By Jennifer Boggs
Managing Editor

Tuesday, June 12, 2012
Genentech Inc. said it will be able to meet demand for newly approved Perjeta (pertuzumab), which it plans to roll out within the next two weeks, though the San Francisco-based biotech acknowledged it will have to resolve a manufacturing issue that could affect future supplies of the HER2-positive breast cancer drug.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription